Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 14,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Type 1 Diabetes Mellitus, Autoimmune Diabetes, Juvenile-Onset Diabetes, Diabetes, Mellitus, Type 1
Interventions: Hybrid Closed-loop System, Sensor-augmented pump; Device
Lead sponsor: Bruce A. Buckingham; Other
Eligibility: 10 Years to 35 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Relapsing Multiple Sclerosis
Interventions: BIIB017 (peginterferon beta-1a), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 12
States / cities: Phoenix, Arizona • Ponte Vedra Beach, Florida • Atlanta, Georgia + 9 more

Conditions: Schizophrenia
Interventions: Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo, Paliperidone palmitate 100 mg eq.; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Anaheim, California • Cerritos, California • Escondido, California + 29 more

Conditions: Diabetes Mellitus
Interventions: AMG 876; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Chula Vista, California • Miramar, Florida • Overland Park, Kansas + 3 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Brexpiprazole, ADT; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more

Conditions: Recent Onset type1 Diabetes
Interventions: Ladarixin, Placebo; Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 14 Years to 45 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 20 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Topiramate; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Occlusive Stroke
Interventions: Asahi Chikai Black 18 neurovascular guidewire; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Plaque Psoriasis
Interventions: Belumosudil, Placebo; Drug
Lead sponsor: Kadmon Corporation, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 14
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 11 more

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 64
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more

Conditions: Healthy Adult Subjects
Interventions: ONO-7746; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cystic Fibrosis
Interventions: VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 30
States / cities: Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more

Conditions: Osteogenesis Imperfecta
Interventions: Setrusumab, Placebo; Biological · Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 5 Years to 25 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 19 more

Conditions: Systemic Lupus Erythematosus
Interventions: Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Torrance, California • Brandon, Florida • Miami, Florida + 10 more

Conditions: Drug Safety
Interventions: Placebo, VIA-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Obstructed Defecation Syndrome (ODS)
Interventions: Botulinum Toxin-A, Normal Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Eosinophilic Esophagitis
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Metastatic Melanoma
Interventions: Allovectin-7®, Dacarbazine (DTIC), Temozolomide (TMZ); Biological · Drug
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 27
States / cities: Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 21 more

Conditions: Liver Transplantation
Interventions: Liver Machine Perfusion (MP) device; Device
Lead sponsor: Koji Hashimoto; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Alzheimer Disease
Interventions: Placebo oral tablet, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Gilbert, Arizona • Surprise, Arizona • Miami, Florida + 6 more

Conditions: Crohn's Disease
Interventions: Epanova™ (Omega-3 Free Fatty Acids); Drug
Lead sponsor: Tillotts Pharma AG; Industry
Eligibility: 16 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 10
States / cities: Atlanta, Georgia • Chicago, Illinois • Urbana, Illinois + 6 more

Conditions: Major Depressive Disorder (MDD)
Interventions: agomelatine, placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 51
States / cities: Mesa, Arizona • Los Angeles, California • Oceanside, California + 42 more

Conditions: Generalized Myasthenia Gravis
Interventions: Satralizumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Los Angeles, California • Orange, California • Pasadena, California + 3 more

Conditions: Actinic Keratoses
Interventions: Cryotherapy, 5Fluorouracil; Procedure · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Medtronic Minimed Overnight Closed-Loop System

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

Multiple Ascending Dose Study in Subjects With Type 2 Diabetes

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder

SURE 18 Registry -Asahi Chikai Black 18 in LVO Stroke

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

ONO-7746 Study in Healthy Adult Subjects

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Setrusumab vs Placebo for Osteogenesis Imperfecta

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Effects of Botox in Obstructed Defecation Syndrome

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

Sequential Hypo- and Normo-thermic Perfusion to Preserve Extended Criteria Donor Livers for Transplantation

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis